Notícias

Regularization of Cannabis-Based Products for Veterinary Use

Publicado em 12/03/2025
12:35

Publicado em 12/03/2025
12:35

Understand how the new measure impacts the regulation of veterinary products and how QR Group can help companies in the process.

On October 30, ANVISA’s Collegiate Board approved a measure that allows the regularization of cannabis-based products for veterinary use by the Ministry of Agriculture and Livestock (MAPA). The decision amends Ordinance SVS/MS 344/1998, allowing veterinarians to prescribe these products under strict control. QR Group, a specialist in health product regulation, is prepared to help companies meet the new requirements and ensure compliance with regulatory bodies.

Impacts of the Regularization of Cannabis Products on the Veterinary Sector

The measure establishes that MAPA will be the body responsible for the regularization of Cannabis-based veterinary products for sale in Brazil. Veterinarians registered with the Federal Council of Veterinary Medicine (CFMV) may prescribe:

Cannabis-based medicines registered with ANVISA;
Cannabis products with health authorization according to RDC 327/2019;
Cannabis-based veterinary products regularized by MAPA.

The products must be prescribed in special prescriptions, as with other controlled drugs. The handling of cannabis-based products remains prohibited.

How QR Group Ensures Regulatory Compliance

QR Group has expertise in the process of regularization of health products with ANVISA and MAPA. Our specialized team offers complete support for companies that wish to insert Cannabis products in the Brazilian veterinary market, ensuring that all regulatory requirements are met safely and quickly.

Our services include:

Regulatory advice for product registration with MAPA;
Consulting on ANVISA requirements for cannabis-based products;
Support in the petition for sanitary authorization according to RDC 327/2019;
Monitoring of regulatory updates and support in the adequacy of products.

What to Expect from the New Rules?

The official regulation will be published in the Official Gazette of the Union in the coming days. Companies that wish to operate in the sector must prepare to meet the new requirements, ensuring regulatory compliance and access to the Brazilian veterinary market.

Cannabis Medicine or Cannabis Product?

Cannabis products regulated by RDC 327/2019 have a different framework from medicines. While medicines require clinical studies to prove efficacy and safety, Cannabis products can be prescribed without specific indication approved by ANVISA.